Abstract
n-3 polyunsaturated fatty acids (PUFA) have been proposed as potential treatments for human heart failure. The cardioprotective effects of n-3 PUFA are supported by extensive cell culture, animal and human studies. Animal studies with n-3 PUFA have shown marked improvements in many independent risk factors for heart failure, including obesity, type II diabetes, insulin resistance, hypertension and inflammation. However, the evidence from observational studies, randomised controlled trials and meta-analyses that these benefits on risk factors lead to improvements in the symptoms of heart failure in patients is much less convincing. Further, most studies have used marine n-3 PUFA; the role of the plant-derived PUFA, α-linolenic acid (ALA), is even less clear. This discontinuity of scientific evidence from animal to human studies suggests that future studies should focus on defining the optimal dosage range and the efficacy of n-3 PUFA compared to standard treatments using standardised study designs. Further studies on ALA would seem justified.
Keywords: Alpha-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, heart failure, omega-3 fatty acids.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:The Role of n-3 Polyunsaturated Fatty Acids in Human Heart Failure
Volume: 13 Issue: 1
Author(s): Hemant Poudyal and Lindsay Brown
Affiliation:
Keywords: Alpha-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, heart failure, omega-3 fatty acids.
Abstract: n-3 polyunsaturated fatty acids (PUFA) have been proposed as potential treatments for human heart failure. The cardioprotective effects of n-3 PUFA are supported by extensive cell culture, animal and human studies. Animal studies with n-3 PUFA have shown marked improvements in many independent risk factors for heart failure, including obesity, type II diabetes, insulin resistance, hypertension and inflammation. However, the evidence from observational studies, randomised controlled trials and meta-analyses that these benefits on risk factors lead to improvements in the symptoms of heart failure in patients is much less convincing. Further, most studies have used marine n-3 PUFA; the role of the plant-derived PUFA, α-linolenic acid (ALA), is even less clear. This discontinuity of scientific evidence from animal to human studies suggests that future studies should focus on defining the optimal dosage range and the efficacy of n-3 PUFA compared to standard treatments using standardised study designs. Further studies on ALA would seem justified.
Export Options
About this article
Cite this article as:
Poudyal Hemant and Brown Lindsay, The Role of n-3 Polyunsaturated Fatty Acids in Human Heart Failure, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010013
DOI https://dx.doi.org/10.2174/1871530311313010013 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chlorella vulgaris: A Multifunctional Dietary Supplement with Diverse Medicinal Properties
Current Pharmaceutical Design Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme
Current Pharmaceutical Design Value of Carnitine Therapy in Kidney Dialysis Patients and Effects on Cardiac Function from Human and Animal Studies
Current Drug Targets Lung Structural Changes in Chronic Obstructive Pulmonary Diseases
Current Drug Targets - Inflammation & Allergy Preparation and Evaluation of Chitosan Submicroparticles Containing Pilocarpine for Glaucoma Therapy
Current Drug Delivery Subject Index To Volume 2
Current Cardiology Reviews Purification and Kinetics of Bovine Kidney Cortex Glutathione Reductase
Protein & Peptide Letters Dietary Regulation of Glucose Metabolism in Metabolic Syndrome
Current Vascular Pharmacology Aqueous Extract of Matricaria pubescens Exhibits Antihypertensive Activity in L-NAME-induced Hypertensive Rats through its Vasorelaxant Effect
Cardiovascular & Hematological Agents in Medicinal Chemistry Resident and Non-Resident Stem Cells in Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Angiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood Pressure in Pathophysiology
Current Medicinal Chemistry Drug-Induced Hypokalaemia
Current Drug Safety Chronic Methylphenidate-Effects Over Circadian Cycle of Young and Adult Rats Submitted to Open-Field and Object Recognition Tests
Current Neurovascular Research Vascular Dysfunction in Aging: Potential Effects of Resveratrol, an Anti- Inflammatory Phytoestrogen
Current Medicinal Chemistry Doxorubicin-Induced In Vivo Nephrotoxicity Involves Oxidative Stress- Mediated Multiple Pro- and Anti-Apoptotic Signaling Pathways
Current Neurovascular Research Effects of a Hypocaloric Diet on Obesity Biomarkers: Prevention of Low-Grade Inflammation since Childhood
Current Pharmaceutical Design Laboratory Monitoring of Hematological and Hepatic Parameters in Ambulatory Patients Receiving Alpha-Methyldopa in a Nigerian Tertiary Care Setting
Current Drug Safety Cyclo-Oxygenase (COX) Inhibiting Nitric Oxide Donating (CINODs) Drugs: A Review of Their Current Status
Current Topics in Medicinal Chemistry CDK9: Therapeutic Perspective in HCC Therapy
Current Cancer Drug Targets The Effect of Licorice Drink on the Systemic Exposure of Verapamil in Rabbits
Drug Metabolism Letters